Category: ProMIS Neurosciences

PROMIS NEUROSCIENCES APPOINTS DR. JOSE LUIS MOLINUEVO TO ITS SCIENTIFIC ADVISORY BOARD

TORONTO, Ontario and CAMBRIDGE, Mass.—January 15, 2020—ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has welcomed José Luis Molinuevo, MD, PhD,  to its scientific advisory board (SAB). Dr. Molinuevo is an internationally recognized neurologist, …

Continue reading

PROMIS NEUROSCIENCES COMPLETES FIRST CLOSING OF PRIVATE PLACEMENT

TORONTO, Ontario – November 18, 2019 – ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that, further to its news release dated November 13, 2019, it completed on November 15, …

Continue reading

PROMIS NEUROSCIENCES ISSUES CHAIRMAN’S UPDATE MEMORANDUM AND WHITE PAPER ON ALZHEIMER’S DISEASE

TORONTO, Ontario and CAMBRIDGE, MA. — October 24, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has issued a memorandum, compiled by its Executive Chairman of the Board, that provides context for the …

Continue reading

PROMIS NEUROSCIENCES ADVANCES ALS PROGRAM SELECTIVELY TARGETING TOXIC FORM OF TDP-43

TORONTO, Ontario and CAMBRIDGE, Mass. — October 23, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has generated antibody candidates targeting the neurotoxic form of TAR DNA-binding protein 43 (TDP-43), a protein found …

Continue reading

PROMIS NEUROSCIENCES IDENTIFIES NOVEL ANTIBODY CANDIDATES FOR MULTIPLE SYSTEM ATROPHY

TORONTO, Ontario and CAMBRIDGE, Mass. — October 8, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has identified several novel antibody candidates for Multiple System Atrophy (MSA), a severe, Parkinson’s-like disease caused by …

Continue reading